Prevention of disease Archives

Home
/
Projects

Prevention of disease

Prevention of disease refers to the ability of the vaccine to protect individuals from becoming sick from the tuberculosis (TB) bacteria after exposure to it. It does not necessarily prevent a person from getting infected with the TB bacteria.

Accelerating research and development of new vaccines against tuberculosis

2021-2025

Hypothetical vaccines

Reviews progress since the 2021 Global TB Vaccine R&D Roadmap and identifies remaining actions needed to accelerate availability, access and uptake of new TB vaccines

Preparing for Tuberculosis Vaccine M72/AS01E Implementation

2026

M72/AS01e

This correction relates to the global demand forecast for the potential implementation of the M72/AS01E TB vaccine

Insights on the implementation strategies for a potential new tuberculosis vaccine in South Africa

2026

Hypothetical vaccines

Examines how a potential new TB vaccine could be introduced in South Africa. Interviews with 26 stakeholders explored implementation priorities, target populations, vaccine price, cost-effectiveness, regulatory approval, financing, procurement, delivery logistics, vaccine acceptability and lessons from existing vaccination programmes.

Estimating the population impact of new tuberculosis vaccines depending on efficacy against infectious asymptomatic tuberculosis:

2026

Hypothetical vaccines, M72/AS01e

Uses a dynamic TB transmission model to estimate how the population impact of future TB vaccines changes depending on whether vaccines prevent progression to infectious symptomatic TB only, all infectious TB, or all TB disease.

Includion of young adolescents in policy development for new tuberculosis vaccines

2026

M72/AS01e, MTBVAC

Reviews the inclusion of young adolescents aged 9-14 years in policy development for new TB vaccines, including the potential benefits of adolescent vaccination, evidence requirements, trial design, implementation considerations, and integration with existing adolescent vaccination programmes

TB vaccine development: monitoring international patent filings to anticipate access challenges

2025-2026

M72/AS01e, MTBVAC

Maps international patent filings for two late-stage TB vaccine candidates, MTBVAC and M72/AS01E, as well as the QS-21 adjuvant used in M72/AS01E

Research overview-2025: integrating scientific progress to accelerate global tuberculosis elimination

2025-2026

Hypothetical vaccines

Reviews scientific progress in tuberculosis research during 2025 and discusses how advances across different areas can contribute to accelerating global TB eliminated including progress in tuberculosis vaccine development

Tuberculosis policy should shift focus to population-level interventions for greatest impact

2026

Hypothetical vaccines

Uses mathematical modelling to compare the population-level health and economic impacts of TB interventions in Brazil, India and South Africa. It highlights mass vaccination and community-wide screening as interventions with the potential for substantial epidemiological impact.

How to introduce new TB vaccine in adolescents and adults: Insights from Key Stakeholders in Mozambique, Southern Africa

2024-2026

Hypothetical vaccines

Assesses stakeholder perspectives on introducing a new TB vaccine in Mozambique, including with high-risk groups should be prioritised, challenges in reaching different populations, expected vaccine uptake and coverage, and appropriate delivery stategies.

Target Tuberculosis vaccination strategies in the United States

2026

Hypothetical vaccines

Uses a mathematical model to evaluate targeted TB vaccination strategies in the United States. The study examines which high-risk groups should be prioritised for a future adult TB vaccine, including people living with HIV, people with medical comorbidities, and people born outside the United States